ClinicalTrials.gg
RecruitingNCT07188012Updated Nov 5, 2026

Safety and Dystrophin Expression of SPOT-03 in Duchenne Muscular Dystrophy (DMD) Patients

An Early Phase 1 interventional study of SPOT-03 in Duchenne Muscular Dystrophy (DMD), sponsored by Shanghai Siponuoyin Biotechnology Co Ltd. Recruiting at 1 site in China. Open to male participants aged 2 Years to 7 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Shanghai Siponuoyin Biotechnology Co Ltd · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
2 Years to 7 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Muscular Dystrophy, Duchenne with a site in China — 5 open to participants now, 10 under way, 1 of them phase 3. Muscular Dystrophy, Duchenne · China.

Planned enrollment
13th of 17
9 · median 20
Started
2025
with 1 other
Phase 1
7 of 19
3 open now
Registered
17th of 19
by date
Lead sponsor
1 of 19
Shanghai Siponuoyin Biotechnology Co Ltd

Among the 19 studies in Muscular Dystrophy, Duchenne with a site in China, this one is the 13th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2025, is one of 7 in phase 1, and was the 17th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

5 of the 19 studies in Muscular Dystrophy, Duchenne with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 7 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Muscular Dystrophy, Duchenne with a site in China, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the safety and tolerability of SPOT-03 administered by intravenous (IV) infusion to DMD patients. In addition, this study will preliminarily investigate the changes in dystrophin nucleic acid concentration, dystrophin protein expression and engraftment, anti-dystrophin antibodies and cytokine profiles, as well as fat tissue mas and lean tissue mass following SPOT-03 administrations.

Read the detailed description

This is a FIH, open-label, single-arm, and single-center exploratory clinical study of SPOT-03 administered via IV infusion for DMD patients. SPOT-03 is a muscle-targeted extracellular vesicles (EVs) loaded with full-length dystrophin nucleic acid. The targeting ability of SPOT-03 is conferred by molecular targeting peptides on the EVs membrane, enabling the delivery of dystrophin nucleic acid as a gene therapy product for DMD.

The study has two dose groups:

Group I: 4.0E+11 dystrophin nucleic acid copies/kg, administered 8 times Group II: 4.0E+11 dystrophin nucleic acid copies/kg, administered 32 times The study will have a Screening Period of 30 days, during which patients or their legal guardian written informed consent will be obtained before Screening assessments and eligibility will be determined. A total of 6 to 9 DMD patients aged 2 to less than 8 years will be enrolled in this study according to the inclusion criteria. Complete data from at least 3 subjects will be obtained for Group II. All subjects will begin oral tacrolimus (0.05-0.2 mg/kg/d, adjustable according to actual clinical conditions) 3 days before the initial administration of SPOT-03 (D-3) and, with the duration aligned to the treatment schedule: 4 weeks for Group I and 16 weeks for Group II. In group I, the first dose of SPOT-03 will be administered by intravenous infusion on D1, followed by twice a week administration (once every 4 days) for a total of 8 doses. In group II, the first dose of SPOT-03 will be administered by intravenous infusion on D1, followed by twice a week administration (once every 4 days) for a total of 32 doses.

After all subjects in the previous dose group have completed SPOT-03 administrations, the next dose group may proceed after the investigators and sponsors have discussed and determined that there are no serious adverse reactions related to the drug.

Safety tests and evaluations will be conducted for the patients during each administration and follow-up.

03

Conditions studied

  • Duchenne Muscular Dystrophy (DMD)

Keywords

  • Duchenne Muscular Dystrophy
  • North Star Ambulatory Assessment
  • Dystrophin
  • Gene Therapy
  • Extracellular Vesicles
04

Who can participate

Ages eligible
2 Years to 7 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. According to the requirements of the region/country and/or IRB/IEC, the patient and/or legal guardian have signed a written form and are aware of all relevant study content.
  2. Boys aged ≥ 2 years to \< 8 years and capable of walking independently for at least 10 meters.
  3. The medical history includes clinical diagnosis of DMD and confirmed Duchenne mutations using validated genetic testing (MLPA and whole genome sequencing).
  4. Able to tolerate muscle under anesthesia and have no to biopsy.
  5. Heart, liver, lung, and kidney functions are sufficient:

    1. The (LVEF) should be ≥ 50%;
    2. Forced vital capacity (FVC) > 50% of the expected value, and do not require nighttime ventilation;
    3. Patient's (GFR)>30 mL/min/1.73 m2

Exclusion criteria

Exclusion Criteria:

  1. Complications other than DMD that may cause muscle weakness and/or motor dysfunction.
  2. There are severe intellectual disabilities (such as severe autism, severe cognitive impairment, and severe behavioral disorders) that, according to the investigator's judgment, can affect the study.
  3. Hospitalization for respiratory failure within 8 weeks prior to screening.
  4. Asthma or underlying lung diseases that are poorly controlled, such as bronchitis, bronchiectasis, emphysema, or recurrent infectious pneumonia that investigator believes may affect respiratory function.
  5. Severe uncontrolled heart failure ( III-IV), including any of the following conditions:

    1. Intravenous administration of diuretics or positive inotropic drugs is required within 8 weeks prior to screening.
    2. Hospitalization due to worsening heart failure or arrhythmia within 8 weeks prior to screening.
  6. Abnormal laboratory values considered :

    1. GGT > 3 ×
    2. ≥ 3.0 mg/dL
    3. Creatinine ≥ 1.8 mg/dL
    4. \< 8 or > 18 g/dL
    5. White blood cell count > 18,500/μL
  7. Arrhythmias that require anti-arrhythmic treatment.
  8. Subjects who are undergoing therapy.
  9. Has used other gene therapy, drugs, or any treatment aimed at increasing dystrophin expression.
  10. Subjects with a history of major surgeries within 12 weeks prior to the initial infusion or planning to undergo major surgeries (such as scoliosis surgery) during this study.
  11. Subjects who are allergic to investigational products or local aesthetic drugs or have a history of severe allergies or genetic allergic reactions.
  12. Within 6 months prior to the initial infusion, the subjects are exposed to another investigational drug or have participated in an intervention clinical trial.
  13. Subjects with positive core antibody or antibody or antibody during screening.
  14. Investigator believes that the presence of any other serious diseases, medical conditions, or chronic drug treatment needs can pose unnecessary risks to gene transfer.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    8-Dose and 32-Dose

    In Group I, 3 patients will be administered SPOT-03 by intravenous infusion on D1, followed by twice a week administration (once every 4 days) for a total of 8 doses. In Group II, at least 3 patients will be administered SPOT-03 by intravenous infusion on D1, followed by twice a week administration (once every 4 days) for a total of 32 doses.

    Genetic: SPOT-03

Interventions

  • GeneticSPOT-03

    SPOT-03 injection administered via IV infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-Related Adverse Events Following Intravenous (IV) Infusion of SPOT-03 in DMD patients

    Safety and tolerability of SPOT-03 will be assessed by collection and quantification of all adverse events, graded according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: From enrollment through 1-year post-treatment

Secondary outcomes

  1. Concentration of Dystrophin Nucleic Acid in Blood

    Dystrophin nucleic acid concentration measured in blood of DMD patients before and after IV infusion of SPOT-03. Quantification is performed by qPCR.

    Time frame: 70 weeks

  2. Concentration of Dystrophin Nucleic Acid in Muscles

    Dystrophin nucleic acid concentration measured in muscles of DMD patients at baseline, during the treatment (only Group II) and after the last IV infusion (dose 8 for Group I and dose 32 for Group II) of SPOT-03. Quantification is performed by qPCR.

    Time frame: 16 weeks

  3. Percent of Normal Dystrophin Protein Expression in Muscles

    Dystrophin protein measured in muscles of DMD patients at baseline, during the treatment (only Group II) and after the last IV infusion (dose 8 for Group I and dose 32 for Group II) of SPOT-03, expressed as percent of the mean wild-type level in healthy individuals without DMD or Becker muscular dystrophy. Quantification is performed by Western Blot.

    Time frame: 16 weeks

  4. Percentage of Dystrophin-Positive Fibers in Muscles

    Fiber intensity and dystrophin-positive fibers measured in muscles of DMD patients at baseline and after the last IV infusion (dose 8 for Group I and dose 32 for Group II) of SPOT-03. Quantification is performed by Immunofluorescence (IF) / Immunohistochemistry (IHC).

    Time frame: 16 weeks

  5. Concentration of Cytokines in Serum

    Immunogenicity assessment will be measured by evaluating the changes of cytokines levels (TNF-α, INF-γ, IL-2, IL-6, and IL-10) in the serum of DMD patients before and after IV infusion of SPOT-03.

    Time frame: 70 weeks

  6. Concentration of Anti-Dystrophin Antibody in Serum

    Anti-dystrophin antibody concentration measured in the serum of DMD patients before and after IV infusion of SPOT-03. Quantification is performed by enzyme-linked immunosorbent assay (ELISA).

    Time frame: 70 weeks

  7. Adipose Tissue and Lean Tissue Mass (only Group II)

    Adipose tissue and lean tissue mass of DMD patients measured at baseline, after IV infusion of SPOT-03, and during follow-up period. Quantification is performed by Dual-Energy X-ray Absorptiometry (DEXA).

    Time frame: 70 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data will not be shared as this is an early-phase pilot study

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2028, 40 months after the start.

Of 28 phase 1 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's planned 40 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Dec 2026 → Dec 2028 and completion Dec 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2025
First posted
Sep 23, 2025
StartActual
Aug 6, 2025
Primary completionEst.
Dec 2028was Dec 2026
CompletionEst.
Dec 2028was Dec 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Dec 2028
Nov 5, 2026
Study completion
Dec 2026→Dec 2028
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Dec 2026→Dec 2028
    Study completion Dec 2026→Dec 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07188012
Lead sponsor
Shanghai Siponuoyin Biotechnology Co Ltd
Collaborators
Shanghai Children's Medical Center
Responsible party
Sponsor
First posted
Sep 23, 2025
Start date
Aug 6, 2025
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Winston Town
Contact
Winston.town@spotbiosystems.com
212-920-5501
Wang Jiwen
principal investigator · Shanghai Children's Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion